Home About Us Products Clinical Trials News Investors Contact Major Shareholdings The current issued share capital of the Company, including shares issued under its blocklisting facility, is 57,063,623 ordinary shares. No shares are held as treasury. The Directors (together with their families and their family trusts and pension scheme and other arrangements) in aggregate hold 1,004,790 ordinary shares in the Company, representing 1.76% of the Company’s current issued share capital. 12.51% of the issued share capital is not in public hands. The Company has been made aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares: Number of ordinary shares % of issued share capital Obotritia Capital KGaA 10.76% Richard Griffiths and Controlled Undertakings 8.00% Octopus Investments Nominees Ltd 5.89% Rosetta Capital VI GP LP, on behalf of Rosetta Capital VI, LP 5.65% Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP 5.27% The above information was last updated on Thursday 28 October 2021 Section: Investors The financial year in review to March 2021 The financial year in review to March 2020 The financial year in review to March 2019 Email alerts General Meetings Investor Centre Corporate Governance Share Price Information Analyst Research Advisors Webcasts and Presentations Financial Reports Financial Calendar Major Shareholdings RNS Notifications Documents and Circulars Declarations Subscribe here for our Press Releases: The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: I agree Click here © ReNeuron Group plc 2021 All rights reserved Website design by Carr Kamasa Design Privacy Notice Disclaimer